Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2024 | Story Leonie Bolleurs | Photo Kaleidoscope
In a nail-biting Varsity Netball semi-final, UFS KovsieNetball triumphed over defending champions UP Tuks, winning 68-62.

In a nail-biting Varsity Netball semi-final, UFS KovsieNetball triumphed over defending champions UP Tuks (30 September 2024), winning 68-62 in the Callie Human Centre on the UFS Bloemfontein Campus. The victory advances them to the final on Monday next week, where they will face UJ.

Early lead and strong performances

Despite a close first half, Kovsies led 15-13 at the first quarter break and 35-31 at half-time, relying on strong performances from goal shooters Rolene Streutker and Xandri Fourie. The game turned in the third quarter when Kovsies extended their lead to 53-43. Tuks fought back during their power play in the final quarter, but Kovsies' consistent play, supported by a lively home crowd, ensured their victory and advancement to the final.

Fourie was named FNB player of the march.

According to head coach Burta de Kock, teamwork played a vital role. “Each player took responsibility for her role on the court and the players played for each other,” she said.

De Kock said they analysed UP's style of play and identified their attack strategy. “We knew they had an accurate goal, so we focused on disrupting the feed to the goal, which led to more interceptions.”

Preparing for final against UJ

Looking ahead to the final against UJ, De Kock acknowledged the challenge, saying that they expect it to be a tough match. "UJ hasn’t won a final yet, and their hearts are set on winning. But we are also ready to take excellence to the court and finish the season on a high,” she commented, "because we have brilliant players, each one understanding her responsibility."

To ensure that the KovsieNetball team is well prepared for this critical match, they are supported by an experienced and dedicated coaching staff, each playing an important role in their success. Leading the charge is De Kock, who guided the team to multiple victories. During her years at KovsieSport, she has developed around 20 Protea players. Defence coach Karla Pretorius, currently also the vice-captain of the Spar Proteas, brings a wealth of international experience to strengthen the team's defence. Attack coach Khanyisa Chawane, now also the captain of the Spar Proteas, focuses on sharpening the offensive strategy. Team manager Ané Retief ensures smooth operations behind the scenes, making this dynamic team an unstoppable force on the court. She is also part of the Protea squad that will represent South Africa at the Fast5 World Series in New Zealand in November.

The Varsity Netball final is set for Monday 7 October at 19:00 in the Callie Human Centre. A limited number of tickets will be available at www.varsitysportsa.com so, supporters are encouraged to get theirs as soon as possible. De Kock expressed her gratitude to the fans, saying, “Without your support, we couldn’t have done it.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept